A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy.
10.3724/zdxbyxb-2023-0258
- Author:
Bo ZHANG
1
;
Kezhong TANG
2
;
Xin DONG
3
Author Information
1. Department of Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. jjs10@zju.edu.cn.
2. Department of Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
3. Department of Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. dongxin@zju.edu.cn.
- Publication Type:Journal Article
- Keywords:
Case report;
Chemotherapy;
Immunotherapy;
Pancreatic cancer;
Targeted therapy;
Tumor microenvironment
- MeSH:
Male;
Humans;
Aged;
Pancreatic Neoplasms/drug therapy*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Adenocarcinoma;
Neoplasm Recurrence, Local/surgery*;
Immunotherapy;
Liver Neoplasms/therapy*;
Pancreatectomy
- From:
Journal of Zhejiang University. Medical sciences
2023;52(5):578-582
- CountryChina
- Language:English
-
Abstract:
A 68-year-old male was admitted due to fatigue and poor appetite and diagnosed pathologically as pancreatic adenocarcinoma with liver metastasis. The tumor marker carbohydrate antigen 199 (CA199) level was 2003.4 U/mL. The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (penpulimab). However, the tumor did not shrink and CA199 level was even higher. Anlotinib was added from the 3rd cycle, and the size of primary tumor and metastatic lesions were significantly reduced. Laparoscopic distal pancreatectomy and splenectomy as well as liver metastasis resection was performed. Three cycles of combined therapy were adopted after surgery followed by maintenance therapy with anlotinib plus penpulimab. There was no evidence of tumor recurrence during the follow-up (nearly 19 months since diagnosis).
